MEDINCELL SA (MEDCL.PA) Forecast, Price Target & Analyst Ratings

EPA:MEDCL • FR0004065605

Current stock price

20.46 EUR
-0.52 (-2.48%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MEDINCELL SA (MEDCL.PA).

Forecast Snapshot

Consensus Price Target

Price Target
€35.97
+ 75.80% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
N/A
Period
Q4 / 2026
EPS Estimate
€0.02
Revenue Estimate
18.988M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
85.88%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
€35.97
Upside
+ 75.80%
From current price of €20.46 to mean target of €35.97, Based on 17 analyst forecasts
Low
€29.80
Median
€34.17
High
€52.50

Price Target Revisions

1 Month
0.00%
3 Months
1.73%

Price Target Summary

17 Wall Street analysts provided a forecast for the next 12 months for MEDCL.PA. The average price target is 35.97 EUR. This implies a price increase of 75.8% is expected in the next year compared to the current price of 20.46.
The average price target has been revised upward by 1.73% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

MEDCL Current Analyst RatingMEDCL Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8

Analyst Ratings History

MEDCL Historical Analyst RatingsMEDCL Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15

Analyst Ratings Consensus

ChartMill Buy Consensus
85.88%
MEDCL.PA was analyzed by 17 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about MEDCL.PA.
In the previous month the buy percentage consensus was at a similar level.
MEDCL.PA was analyzed by 17 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-01-26PORTZAMPARC BNP PARIBASMaintains Buy -> Buy
2023-08-30MIDCAP PARTNERSMaintains Buy -> Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A
Period
Q4 / 2026
EPS Estimate
€0.02
Revenue Estimate
18.988M
Revenue Q2Q
13.03%
EPS Q2Q
115.85%
Number of Analysts
5

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
MEDCL.PA revenue by date.MEDCL.PA revenue by date.
9.889M
141.78%		9.032M
-8.67%		25.419M
181.43%		33.418M
31.47%		67.609M
102.31%		140.31M
107.53%		188.07M
34.04%		161.57M
-14.09%		156.39M
-3.21%		254.78M
62.91%		189.53M
-25.61%
EBITDA
YoY % growth
MEDCL.PA ebitda by date.MEDCL.PA ebitda by date.
-22.387M
-0.40%		-19.125M
14.57%		-8.751M
54.24%		-2.534M
71.05%		31.106M
1,327.64%		69.062M
122.02%		113.8M
64.78%		N/AN/AN/AN/A
EBIT
YoY % growth
MEDCL.PA ebit by date.MEDCL.PA ebit by date.
-24.052M
-1.00%		-20.844M
13.34%		-10.741M
48.47%		-6.659M
38.01%		29.529M
543.48%		96.885M
228.10%		137.49M
41.91%		117.35M
-14.65%		197.39M
68.21%		196.04M
-0.68%		130.02M
-33.68%
Operating Margin
MEDCL.PA operating margin by date.MEDCL.PA operating margin by date.
-243.22%-230.78%-42.26%-19.92%43.68%69.05%73.11%72.63%126.22%76.94%68.60%
EPS
YoY % growth
MEDCL.PA eps by date.MEDCL.PA eps by date.
N/A
-46.42%		N/A
-13.12%		N/A
20.47%		-0.29
61.93%		0.59
301.77%		0.94
60.53%		2.99
217.41%		4.26
42.28%		4.47
5.01%		8.47
89.54%		5.74
-32.25%

All data in EUR

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q4 / 26
EPS
Q2Q % growth		0.02
115.85%
Revenue
Q2Q % growth		18.988M
13.03%
EBITDA
Q2Q % growth
100.00%
EBIT
Q2Q % growth		-3.352M
-4.36%

All data in EUR

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

MEDCL.PA Yearly Revenue VS EstimatesMEDCL.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M 200M 250M
MEDCL.PA Yearly EPS VS EstimatesMEDCL.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 4 6 8

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
47.87%
EPS Next 5 Year
49.90%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
66.79%
Revenue Next 5 Year
39.81%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
98.32%
EBIT Next 5 Year
84.38%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

MEDINCELL SA / MEDCL.PA Forecast FAQ

What is the average price target for MEDINCELL SA (MEDCL.PA) stock?

17 analysts have analysed MEDCL.PA and the average price target is 35.97 EUR. This implies a price increase of 75.8% is expected in the next year compared to the current price of 20.46.

Can you provide the consensus estimates for MEDINCELL SA next earnings?

The consensus EPS estimate for the next earnings of MEDINCELL SA (MEDCL.PA) is 0.02 EUR and the consensus revenue estimate is 18.99M EUR.

What is the expected long term growth rate for MEDINCELL SA (MEDCL.PA)?

The expected long term growth rate for MEDINCELL SA (MEDCL.PA) is 66.79%.